Refractory Duodenal Crohn's Disease Successfully Treated with Infliximab.
- Author:
You Lim KIM
1
;
Young Sook PARK
;
Eun Kyoung PARK
;
Dae Rim PARK
;
Gyu Sik CHOI
;
Sang Bong AHN
;
Seong Hwan KIM
;
Yun Ju JO
Author Information
- Publication Type:Case Report
- Keywords: Crohn's disease; Duodenum; Infliximab
- MeSH: Anal Canal; Azathioprine; Colon; Congenital Abnormalities; Crohn Disease*; Duodenum; Endoscopy; Endoscopy, Digestive System; Follow-Up Studies; Gastrointestinal Tract; Humans; Infliximab; Mesalamine; Middle Aged; Mouth; Proton Pumps; Ulcer
- From:Intestinal Research 2014;12(1):66-69
- CountryRepublic of Korea
- Language:English
- Abstract: Crohn's disease (CD) may involve any part of the gastrointestinal tract, from the mouth to the anus. Approximately >90% of cases occur in the small bowel and colon. Upper gastrointestinal involvement, especially duodenal manifestation, is relatively rare. Therefore, adequate medical treatment for duodenal CD has not yet been established. We report a case of CD with duodenal involvement. A 46-year-old man with Crohn's ileocolitis presented to our hospital with right upper quadrant pain. An endoscopy showed a deep excavated ulcer with deformity at the duodenal bulb, and he was initially treated with azathioprine (1 mg/kg), Pentasa (3.0 g/day), and a proton pump inhibitor for 1 year. However, the deep ulcer did not heal. Therefore, infliximab infusion therapy was initiated, and the duodenal lesion completely resolved on follow-up esophagogastroduodenoscopy. We report a case of duodenal CD that completely resolved following infliximab infusion, with a review of the literature.
